CAREMAX INC (CMAX) Forecast, Price Target & Analyst Ratings
NASDAQ:CMAX • US14171W2026
0.4215 USD
-0.15 (-26.22%)
At close: Nov 27, 2024
0.3089 USD
-0.11 (-26.71%)
After Hours: 11/27/2024, 9:32:53 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CAREMAX INC (CMAX).
Forecast Snapshot
Consensus Price Target
$43.25
+ 10,160.50% Upside
Next Earnings Forecast
Release DateN/A
PeriodQ3 / 2024
EPS Estimate-$6.95
Revenue Estimate200.01M
ChartMill Buy Consensus
45.71%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$43.25
Upside
+ 10,160.50%
From current price of $0.42 to mean target of $43.25, Based on 7 analyst forecasts
Low
$2.22
Median
$5.10
High
$126.00
Price Target Revisions
1 Month
0.00%
3 Months
30.26%
Price Target Summary
7 Wall Street analysts provided a forecast for the next 12 months for CMAX. The average price target is 43.25 USD. This implies a price increase of 10160.5% is expected in the next year compared to the current price of 0.4215.
The average price target has been revised upward by 30.26% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
45.71%
CMAX was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about CMAX.
In the previous month the buy percentage consensus was at a similar level.
CMAX was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-04-01 | UBS | Maintains | Neutral -> Neutral |
| 2023-11-17 | UBS | Downgrade | Buy -> Neutral |
| 2023-11-10 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2023-01-06 | UBS | Maintains | Buy |
| 2022-09-07 | Truist Securities | Initiate | Hold |
| 2021-10-20 | Jefferies | Initiate | Buy |
| 2021-09-13 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2021-09-10 | Cowen & Co. | Initiate | Outperform |
| 2021-07-01 | Piper Sandler | Initiate | Neutral |
Next Earnings Forecast Details
Next Earnings Details
Release DateN/A
PeriodQ3 / 2024
EPS Estimate-$6.95
Revenue Estimate200.01M
Revenue Q2Q-0.91%
EPS Q2Q74.81%
Number of Analysts5
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.00%
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
The next earnings revenue estimate has been revised downward by 0% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 295.762M | 631.132M 113.39% | 751.102M 19.01% | 848.79M 13.01% | 1.124B 32.42% | 1.281B 13.97% | 1.405B 9.68% | 1.706B 21.42% | 1.956B 14.65% | 2.228B 13.91% | 2.519B 13.06% | |
| EBITDA YoY % growth | -14.086M | -7.281M 48.31% | -81.057M -1,013.27% | -43.146M 46.77% | -3.639M 91.57% | 47.519M 1,405.70% | 45.492M -4.27% | 47.226M 3.81% | 47.634M 0.86% | 48.348M 1.50% | 54.978M 13.71% | |
| EBIT YoY % growth | -27.301M -580.48% | -29M -6.22% | -108.844M -275.32% | -61.195M 43.78% | -35.756M 41.57% | 11.796M 132.99% | -7.752M -165.72% | -6.426M 17.11% | -4.488M 30.16% | -2.754M 38.64% | 4.59M 266.67% | |
| Operating Margin | -9.23% | -4.59% | -14.49% | -7.21% | -3.18% | 0.92% | -0.55% | -0.38% | -0.23% | -0.12% | 0.18% | |
| EPS YoY % growth | N/A | 7.20 203.80% | -183.03 -2,642.08% | -29.73 83.76% | -19.60 34.08% | -8.74 55.43% | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 24 | Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -6.95 74.81% | -6.04 95.15% | -5.42 52.86% | -5.75 41.66% | -5.20 25.24% | -4.54 24.75% | -2.09 61.39% | -1.81 68.62% | -1.35 74.09% | -0.96 78.90% |
| Revenue Q2Q % growth | 200.01M -0.91% | 195.8M 28.96% | 257.3M 10.79% | 302.19M 52.14% | 283.46M 41.72% | 281.08M 43.55% | 351.16M 36.48% | 379.64M 25.63% | 341.5M 20.48% | 338.34M 20.37% |
| EBITDA Q2Q % growth | -11.64M -222.54% | -3.947M 92.95% | -1.54M 89.74% | -3.799M 41.85% | -1.184M 89.83% | 2.878M 172.92% | 8.18M 631.28% | 12.23M 421.93% | 17.483M 1,576.33% | 22.246M 672.97% |
| EBIT Q2Q % growth | -12.577M -17.12% | -20.91M 75.05% | -9.16M 57.80% | -12.107M 38.70% | -9.251M 26.44% | -5.238M 74.95% | 2.917M 131.85% | 6.538M 154.00% | 12.362M 233.62% | 17.177M 427.95% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.98%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
16.94%
Revenue Next 5 Year
16.33%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
30.61%
EBIT Next 5 Year
17.36%
CAREMAX INC / CMAX Forecast FAQ
What is the average price target for CAREMAX INC (CMAX) stock?
7 analysts have analysed CMAX and the average price target is 43.25 USD. This implies a price increase of 10160.5% is expected in the next year compared to the current price of 0.4215.
What are the consensus estimates for CMAX stock next earnings?
The consensus EPS estimate for the next earnings of CAREMAX INC (CMAX) is -6.95 USD and the consensus revenue estimate is 200.01M USD.
Can you provide the expected long term growth rate for CAREMAX INC stock?
The expected long term growth rate for CAREMAX INC (CMAX) is 16.94%.